About: Hydroxychloroquine plus standard care compared with the standard care alone in COVID-19: a meta-analysis of randomized controlled trials

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Hydroxychloroquine plus standard care compared with the standard care alone in COVID-19: a meta-analysis of randomized controlled trials Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Hydroxychloroquine plus standard care compared with the standard care alone in COVID-19: a meta-analysis of randomized controlled trials
Creator	Amani, Bahman Amani, Behnam Khanijahani, Ahmad
Source	MedRxiv
abstract	Background & Objective: The efficacy and safety of Hydroxychloroquine (HCQ) in treating coronavirus disease COVID-19 pandemic is disputed. This study aimed to examine the efficacy and safety of HCQ plus standard of care in COVID-19 patients. Methods: PubMed, The Cochrane Library, Embase, and web of sciences were searched up to June 1, 2020. The references list of the key studies was reviewed for additional relevant resources. Clinical studies registry databases were searched for identifying potential clinical trials. The quality of the included studies was evaluated using the Cochrane Collaborations tool. Meta-analysis was performed using RevMan software (version 5.3). Results: Three randomized controlled trials with total number of 242 patients were identified eligible for meta-analysis. No significant differences were observed between HCQ and standard care in terms of viral clearance (Risk ratio [RR] = 1.03; 95% confidence interval [CI] = 0.91, 1.16; P= 0.68), disease progression (RR=0.92; 95% CI= 0.10, 0.81; P=0.94), Chest CT (RR=1.40; 95% CI= 1.03, 1.91; P=0.03). There is a significant difference between HCQ and standard care for adverse events (RR=2.88; 95% CI= 1.50, 5.54; P=0.002). Conclusion: Although the current meta-analysis failed to confirm the efficacy and safety of HCQ in the treatment of COVID-19 patients, further rigorous randomized clinical trials are necessary to evaluate conclusively the efficacy and safety of HCQ against COVID-19. Keyword: Coronavirus Disease; COVID-19; SARS-CoV-2; Hydroxychloroquine; Efficacy; Safety
has issue date	2020-06-12(xsd:dateTime)
bibo:doi	10.1101/2020.06.05.20122705
has license	medrxiv
sha1sum (hex)	c014305a88e939a813b0664319a4f67190d96c52
schema:url	https://doi.org/10.1101/2020.06.05.20122705
resource representing a document's title	Hydroxychloroquine plus standard care compared with the standard care alone in COVID-19: a meta-analysis of randomized controlled trials
resource representing a document's body	covid:c014305a88e939a813b0664319a4f67190d96c52#body_text
is schema:about of	named entity 'Hydroxychloroquine' named entity 'COVID-19' named entity 'safety' named entity 'care' named entity 'COVID-19' named entity 'COVID-19 pandemic' named entity 'Hydroxychloroquine' named entity 'preprint' named entity 'randomly assigned' named entity 'SARS-CoV-2' named entity 'open-label' named entity 'medRxiv' named entity 'COVID-19' named entity 'COVID' named entity 'preprint' named entity 'preprint' named entity 'HCQ' named entity 'preprint' named entity 'headache' named entity 'medRxiv' named entity 'adverse effects' named entity 'synergistic effect' named entity 'significant difference' named entity 'synergistic effect' named entity 'metabolism' named entity 'HCQ' named entity 'HCQ' named entity 'medRxiv' named entity 'Standard treatment' named entity 'meta-analysis' named entity 'randomly assigned' named entity 'HCQ' named entity 'study protocol' named entity 'COVID-19' named entity 'randomized controlled trials' named entity 'COVID' named entity 'Statistical heterogeneity' named entity 'systematic review' named entity 'COVID' named entity 'preprint' named entity 'azithromycin' named entity 'preprint' named entity 'review articles' named entity 'HCQ' named entity 'preprint' named entity 'preprint' named entity 'Azithromycin' named entity 'COVID' named entity 'medRxiv' named entity 'Hydroxychloroquine' named entity 'animal models' named entity 'Adverse effects' named entity 'Cochrane Collaboration' named entity 'adverse effect' named entity 'meta-analyses' named entity 'Randomized controlled trial' named entity 'COVID' named entity 'preprint' named entity 'cough' named entity 'meta-analyses' named entity 'preprint' named entity 'letter to the editor' named entity 'meta-analysis' named entity 'adverse events' named entity 'peer review' named entity 'significance level' named entity '2019-nCoV' named entity 'COVID-19' named entity 'medRxiv' named entity 'June 12' named entity 'COVID-19' named entity 'AHRQ' named entity 'HCQ' named entity 'follow-up' named entity 'control groups' named entity 'PROSPERO' named entity 'study design' named entity 'Retinopathy' named entity 'preprint' named entity 'Clinical trial' named entity 'COVID' named entity 'HCQ' named entity 'Embase'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software